GleamWall
中文EN

RTGN RetinalGenix Technologies Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1836295 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-34,441.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets46,768.1%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-26,393.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$111,573$66,406$117,064$34,942$20,454$14,430$13,214$104,271
SG&A expense$275,407$212,254$262,149$305,871$270,153$383,729$341,203$392,109
Interest expense$1,525$3,955$1,260$1,068$958$1,070$909$960
Net income-$433,025-$307,397-$590,489-$623,127-$568,791-$649,418-$587,259-$867,027
EPS (basic)-0.02-0.02-0.03—-0.03-0.03-0.03—
EPS (diluted)-0.02-0.02-0.03—-0.03-0.03-0.03—
Weighted avg. shares (diluted)19.07M18.81M18.75M—18.58M18.33M18.52M—
Balance sheet
Cash & equivalents$5$27,232$180$14,774$92$839$3,711$6,060
Current assets$5$27,232$180$14,774$92$839$3,711$6,060
PP&E, net——————$31$56
Total assets$4,346$32,215$5,805$21,041$7,001$8,388$11,931$14,946
Current liabilities$2.03M$2.67M$2.56M$2.32M$2.17M$1.98M$1.67M$1.47M
Total liabilities$2.03M$2.67M$2.56M$2.32M$2.18M$1.99M$1.68M$1.48M
Shareholders' equity-$2.03M-$2.64M-$2.56M-$2.30M-$2.17M-$1.98M-$1.67M-$1.46M
Shares outstanding19.29M18.84M18.75M18.75M18.60M18.56M18.52M18.52M
Cash flow statement
Operating cash flow-$82,484-$136,671-$109,213-$128,219-$103,837-$139,072-$187,222-$186,390
Financing cash flow$55,257$163,723$94,619$142,901$103,090$136,200$184,873$113,361
Depreciation & amortization———$0$0$31$25$25
Stock-based compensation$44,520$24,782$210,016$281,246$277,226$250,189$231,933$369,687

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.